SAN CARLOS, Calif., May 2 /PRNewswire-FirstCall/ -- NeurogesX, Inc. announced today the initial public offering of 4,000,000 shares of common stock at a price to the public of $11.00 per share. The Company has granted an option to the underwriters to purchase up to an additional 600,000 shares to cover over-allotments, if any.
NeurogesX's common stock will trade on the NASDAQ Global Market under the symbol "NGSX." The offering is expected to close on May 7, 2007, subject to customary closing conditions.
Morgan Stanley & Co. Incorporated acted as the sole book running and lead manager for the offering. Pacific Growth Equities, LLC, Lazard Capital Markets LLC and Susquehanna Financial Group, LLLP acted as co-managers for the offering.
The offering is made only by means of a prospectus, copies of which may be obtained from the Morgan Stanley & Co. Incorporated prospectus department, 180 Varick Street, New York, NY 10014, Attention: Prospectus Department, by telephone at (212) 761-6775 or by emailing prospectus@morganstanley.com.
A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About NeurogesX, Inc.
NeurogesX is a biopharmaceutical company focused on developing novel pain management therapies for neuropathic pain.
NeurogesX Stephen Ghiglieri (650) 508-2116 The Ruth Group Investors / Media Stephanie Carrington / Jason Rando (646) 536-7017 / 7025 scarrington@theruthgroup.comjrando@theruthgroup.com
NeurogesX, Inc.CONTACT: Stephen Ghiglieri of NeurogesX, Inc., +1-650-508-2116; orInvestors - Media, Stephanie Carrington, +1-646-536-7017,scarrington@theruthgroup.com, or Jason Rando, +1-646-536-7025,jrando@theruthgroup.com, both of The Ruth Group
